← All indications
Spinal Cord Injuries
Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).
Subtype terms (3)
More specific conditions that are subtypes of Spinal Cord Injuries in the MeSH hierarchy.
- Autonomic Dysreflexia
7 drugs approved
- Central Cord Syndrome
- Spinal Cord Compression
6 drugs (4 approved, 2 experimental)
Drugs by status
Approved for this indication (3)
Phase 4 trials (39)
- denosumab
- romosozumab
- amitriptyline
- mecamylamine
- tadalafil
- exenatide
- oxycodone
- cycloserine
- darifenacin
- droxidopa
- fidaxomicin
- gabapentin
- levetiracetam
- neuroaid
- rimabotulinumtoxinB
- vitamin c
- human milk
- oxybutynin
- lidocaine
- teriparatide
- ramelteon
- semaglutide
- trazodone
- trospium
- vancomycin
- vardenafil
- zoledronic acid
- killed enterotoxigenic escherichia coli vaccine
- neostigmine
- sildenafil
- +9 more
Phase 3 trials (34)
- dalfampridine
- vitamin d3
- methylprednisolone
- epoetin
- brivaracetam
- cethrin
- fgf-1
- somatropin
- glycopyrronium
- levodopa
- carbidopa
- lactobacillus gasseri
- metamizole
- nitro arginine
- tizanidine
- riluzole
- cannabis
- risedronate
- tirilazad mesylate
- testosterone
- tramadol
- vx-210
- human placental derived stem cells
- gentamicin
- fenofibrate
- lactobacillus crispatus
- lactobacillus jensenii
- minocycline
- midodrine
- aminophenazone cyclamate
- +4 more
Phase 2 trials (70)
- simvastatin
- 2-hydroxyoleic acid
- nitroglycerin
- calcium carbonate
- buspirone
- mirabegron
- bone autograft
- castor oil
- nabilone
- cannabidiol
- essential oils
- fab117-hc
- imatinib
- glyburide
- naltrexone
- calcium
- bone marrow derived mesenchymal stem cells
- rosuvastatin
- nerispirdine
- istradefylline
- kai-1678
- levocarnitine
- lithium
- allogeneic stem cells
- alendronic acid
- caffeine
- allogeneic hematopoietic stem cells
- rimonabant
- sun13837
- finasteride
- +40 more
Phase 1 trials (26)
- melatonin
- mometasone
- ibuprofen
- salmeterol
- escitalopram
- grnopc1
- ritobegron
- platelet-rich plasma
- pittsburgh compound b
- collagen
- autologous human schwann cells
- e. coli 83972
- human spinal cord stem cells
- autologous adipose tissue
- atinumab
- onabotulinumtoxinA
- lactobacillus reuteri
- 18f-mk6240
- ec5026
- allorx stem cells®
- f-18 3f4ap
- almb-0166
- cris100
- mtr-601
- ng004
- opc1
Other trials (39)
- florbetaben F-18
- albuvirtide
- vitamin e
- oxandrolone
- carbon dioxide
- capsaicin
- cranberry
- cyproheptadine
- enalapril
- glp-2
- insulin human
- acetylcholine chloride
- lavender
- memantine
- gip
- salsalate
- creatine
- high-selenium yeast
- phenol
- lactobacillus plantarum
- oat bran
- prunus domestica
- rivaroxaban
- albuterol
- methadone
- isradipine
- enterococcus faecium
- beta-alanine
- sodium phosphate
- prednisolone
- +9 more
Organizations
Organization Involved with Phase 4 Indications (58)
- Solstice Neurosciences
- Takeda
- Eli Lilly
- Pfizer
- Allergan
- Bayer
- Cubist
- Medy-Tox
- Dentsply International
- Moleac Pte Ltd.
- Ontario Neurotrauma Foundation
- National Institutes of Health (NIH)
- Hospital Nacional de Parapléjicos de Toledo
- Aarhus University
- University of Manitoba
- Baylor University
- Case Western Reserve University
- China Rehabilitation Research Center
- Craig Hospital
- Georgetown University
- University of Washington
- Hoosier Cancer Research Network
- Metro Health, Michigan
- Ilsan Hospital
- National University of Malaysia
- New York University
- Northwestern University
- Osaka University
- Seoul National University
- Simon Fraser University
- +28 more
Organization Involved with Phase 3 Indications (39)
- Acorda Therapeutics
- Vertex
- Elan Pharmaceuticals
- ICOS
- Ipsen
- Purdue Pharmaceuticals
- BioAxone BioSciences, Inc.
- GlaxoSmithKline
- GW Pharmaceuticals Ltd.
- Kringle Pharma, Inc.
- Eusol
- Kessler Foundation
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute on Drug Abuse (NIDA)
- Brock University
- University of London
- Instituto Mexicano del Seguro Social
- Masaryk University
- Rick Hansen Institute
- Thomas Jefferson University
- University of Louisville
- University of Milan
- Yale University
- University of Calgary
- University of California, Davis
- University of California, San Diego
- University of Copenhagen
- University of Utah
- Vancouver Coastal Health
- Government of Mexico
- +9 more
Organization Involved with Phase 2 Indications (89)
- AbbVie
- Daiichi Sankyo
- KAI Pharmaceuticals
- XenoPort, Inc.
- Vernalis
- Avigen
- Recordati
- Sanofi
- Novartis
- Ferrer Internacional S.A.
- Indivior Inc.
- RDD Pharma Ltd
- Healthpoint
- Nordic Life Science Pipeline Inc.
- Pharmazz, Inc.
- Stem Cells Arabia
- StemCells, Inc.
- Translational Biosciences
- North Florida Foundation for Research and Education
- Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
- Huazhong University of Science and Technology
- Medical University of Graz
- Banc de Sang i Teixits
- Tzu Chi University
- Cancer Research Network
- China Spinal Cord Injury Network
- Harvard University
- Hospital Sao Rafael
- Indian Council of Medical Research
- Indian Spinal Injuries Centre
- +59 more
Organization Involved with Phase 1 Indications (17)
- Chelsea Therapeutics
- Bukwang Pharmaceutical
- Boehringer Ingelheim
- Seneca Biopharma, Inc.
- TCA Cellular Therapy
- Pakistan Army
- Advent Health
- Korea University
- Memorial Hermann Health System
- University of Lausanne
- Soochow University
- University of Texas at Houston
- Humboldt University
- University of Texas, San Antonio
- The Miami Project to Cure Paralysis
- The Institute for Rehabilitation and Research (TIRR) Foundation
- Ecole Polytechnique Fédérale de Lausanne
Organization Involved with Other Experimental Indications (13)
- Centro de Reabilitação e Readaptação Dr. Henrique Santillo
- University of Pittsburgh
- University of Medicine and Dentistry of New Jersey
- University of Rochester
- Virginia Commonwealth University
- Dalian Medical University
- Uppsala University
- University of Porto
- University of Sao Paulo
- Hope Biosciences
- Shirley Ryan AbilityLab
- Gaziler Physical Medicine and Rehabilitation Education and Research Hospital
- Istanbul Physical Medicine Rehabilitation Training and Research Hospital